Active	Status	Sponsor type	Region	Phase	Filter
5 Active 6 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Williams, Robert D
NCT06098079: Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)	Recruiting	4	8600	US	Naltrexone-Bupropion (NB) Combination, Placebo	Currax Pharmaceuticals	Obesity	01/29	07/29
SWIFT-2, NCT04718103 / 2020-003611-10: A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype	Active, not recruiting	3	397	Europe, Canada, Japan, US, RoW	GSK3511294 (Depemokimab), Placebo	GlaxoSmithKline, Iqvia Pty Ltd	Asthma	04/24	04/24
NCT05243680 / 2020-004334-38: An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)	Recruiting	3	637	Europe, Canada, Japan, US, RoW	GSK3511294 (Depemokimab)	GlaxoSmithKline, Iqvia Pty Ltd	Asthma	05/25	05/25
SUVN-G3031, NCT04072380: A Study to Evaluate Safety, and Efficacy of (Samelisant) in Patients With Narcolepsy With and Without Cataplexy	Completed	2	190	Canada, US	SUVN-G3031, Samelisant, Placebo	Suven Life Sciences Limited	Narcolepsy	06/23	06/23
NCT05823974: A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults	Active, not recruiting	1/2	1256	Europe, Canada, US, RoW	Flu mRNA, GSK4382276A, Control 1, Control 2	GlaxoSmithKline, CureVac	Influenza, Human	07/24	08/24